Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo PeLe: Neoadjuvant Pembrolizumab and Lenvatinib in Resectable Stage III Melanoma
NCT04207086Phase 2Active, not recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Nov 2020
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in melanoma, sponsored by Melanoma Institute Australia. Started Nov 2020; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04207086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207086.